MedTrace Logo

Effect of GLP - 1 (7-36 Amide) on Myocardial Function Following Coronary Artery Bypass (CABG) Surgery

NCT00966654 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2017-07-12

Study results available
· View outcomes & findings →

Summary

This research is being done to see if giving a hormone called GLP-1 can improve heart function and reduce length of stay in the Cardiac Surgical Intensive Care Unit (CSICU) in people who have non-emergent coronary artery bypass graft (CABG) surgery.

Conditions

  • CABG

Interventions

DRUG

Placebo

1.5 pmol/kg/min (5 ng/kg/min) saline infused continuously over 72 hours.

DRUG

GLP-1 (7-36) amide

1.5 pmol/kg/min (5 ng/kg/min) GLP-1 infused continuously over 72 hours.

Sponsors & Collaborators

Principal Investigators

  • Dariush Elahi, PhD · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2009-08-31
Completion
2012-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00966654 on ClinicalTrials.gov